The National Pharmaceutical Pricing Authority cannot currently mandate a 20 percent trade margin cap on non-scheduled medical devices due to existing legal limitations. While regulators are evaluating ways to lower consumer costs, no permanent framework exists to force this price reduction. Investors should monitor potential policy amendments that could impact the profit margins of medical device manufacturers and private hospital chains.
The National Pharmaceutical Pricing Authority (NPPA) currently lacks the legal authority to implement a blanket 20 percent trade margin cap on medical devices. This regulatory limitation means that prices for most hospital consumables remain determined by manufacturers and private hospitals, rather than being fixed by the government.
The Regulatory Framework
The NPPA operates under the Drugs (Prices Control) Order of 2013. Under this existing law, the regulator is authorized to fix ceiling prices only for "scheduled" drugs and a specific, limited set of notified medical devices. The vast majority of hospital consumables, often classified as "non-scheduled" items, currently fall outside the NPPA’s routine price-fixing jurisdiction.
Because of these legal boundaries, the government cannot simply issue an order to cap margins at 20 percent for all devices. To implement such a widespread change, the government would likely need to amend the existing Drugs (Prices Control) Order or introduce a new, comprehensive policy framework. Without these changes, the regulator’s power remains restricted, allowing companies to set their own pricing strategies for non-scheduled products.
Why Controls are Under Debate
Pressure to intervene has been building following investigations into the pricing of essential medical equipment. Recent regulatory probes, including those by the Maharashtra Food and Drug Administration, highlighted large gaps between the procurement cost of items—such as IV infusion sets, catheters, and oxygen masks—and the final price charged to patients in private hospitals.
Parliamentary committees have expressed concern that these high markups increase the financial burden on patients. As a result, officials are exploring ways to bring more medical devices under price control to protect consumers. However, the current lack of a permanent, institutionalized framework has prevented a country-wide margin cap.
Impact and Investor Perspective
For investors, the primary risk lies in the possibility of sudden regulatory shifts. In the past, the government has used emergency powers, such as Paragraph 19 of the Drugs (Prices Control) Order, to intervene during public health crises, such as the temporary price caps imposed on Covid-related devices in 2021. While these were one-off measures, they demonstrate that the government can act quickly when it deems necessary in the public interest.
If the government eventually succeeds in amending the law to allow for permanent margin controls, it could compress the profit margins of medical device manufacturers and impact the service revenue of hospital chains that rely on high markups for consumables. Conversely, as long as the current regulatory status quo continues, these companies maintain the freedom to set their own margins, though they remain subject to potential scrutiny and reputational risks.
The key factor for investors to track is any upcoming movement in the Department of Pharmaceuticals regarding changes to the Drugs (Prices Control) Order. Updates on policy-level decisions regarding Trade Margin Rationalisation will be the most significant indicator of potential margin pressure for the sector.